Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Australian Clinical Labs Ltd ( (AU:ACL) ).
Australian Clinical Labs has continued its on-market share buy-back program, confirming a cumulative repurchase of 8,168,983 ordinary fully paid shares prior to the latest reporting date. The company reported that it bought back a further 50,000 shares on the previous trading day, as part of its ongoing capital management strategy disclosed to the market since October 2025.
The latest notification, dated 5 May 2026, updates investors on the daily progress of the buy-back and follows an earlier announcement made on 1 May 2026. The continued execution of the on-market buy-back may support earnings per share and signal management’s confidence in the company’s valuation, with potential implications for shareholder returns and the stock’s trading dynamics.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.20 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd is an Australian healthcare company operating in the medical diagnostics and pathology testing industry. It provides laboratory testing services to healthcare providers and patients, with its ordinary fully paid shares listed on the ASX under the code ACL.
Average Trading Volume: 862,207
Technical Sentiment Signal: Sell
Current Market Cap: A$360.3M
For detailed information about ACL stock, go to TipRanks’ Stock Analysis page.